logo-loader
viewCannPal Animal Therapeutics Ltd

CannPal Animal Therapeutics delivers a medical cannabis milestone

CannPal is researching the benefits of medical cannabis for companion animals.

1527554275_SleepyPuppy.jpg
CannPal is the only ASX-listed pure animal health company

CannPal Animal Therapeutics Limited (ASX:CP1) has achieved a milestone in entering into a manufacturing agreement with New Zealand based veterinary contract manufacturing organisation, Jaychem Industries Ltd.

The agreement will allow CannPal to proceed with developing DermaCann, a high-quality cannabinoid derived therapeutic that is targeted to meet GMP (Good Manufacturing Processes) standards.

The company has now commissioned pharmaceutical quality assurance and GMP compliance consultants, Seer Pharma, to perform a GMP Inspection of Jaychem to relevant standards that will apply to Dermacann in the company’s target regions.

CannPal is researching and developing medicines derived from cannabinoids to provide veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.

The core strategy is to use compounds derived from cannabis that have been de-risked in clinical humans studies, to progress straight into animal clinical trials.

Quick facts: CannPal Animal Therapeutics Ltd

Price: 0.125 AUD

ASX:CP1
Market: ASX
Market Cap: $11.64 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CannPal Animal Therapeutics Ltd named herein, including the promotion by the Company of CannPal Animal Therapeutics Ltd in any Content on the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CannPal Animal Therapeutics leveraged to 'lucrative potential' of growing market

CannPal Animal Therapeutics Ltd (ASX:CP1) founder and managing director Layton Mills speaks to Proactive Investors about the innovative pet pharmaceutical company, which operates in the medical cannabis space. "The goal for the company is really to develop products that can address clear,...

on 25/6/18

2 min read